Disruptive chemical doping in a ferritin-based iron oxide nanoparticle to decrease r2 and enhance detection with T1-weighted MRI

Contrast Media and Molecular Imaging

Volumn 9, Issue 5, 2014, Pages 323-332

  Clavijo Jordan, M Veronica ^a   Beeman, Scott C ^a   Baldelomar, Edwin J ^a   Bennett, Kevin M ^a,b  

^a Arizona State University   (United States)

^b University of Hawaii at Manoa ^*  (United States)

Author keywords

Ferritin; MRI; Nanoparticles; Tungsten

Indexed keywords

APOFERRITIN; FERRITIN; IRON OXIDE; MAGNETIC NANOPARTICLE; TUNGSTEN; CONTRAST MEDIUM; FERRIC ION; FERRIC OXIDE; MAGNETITE NANOPARTICLE;

ADULT; ANIMAL EXPERIMENT; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; GEL PERMEATION CHROMATOGRAPHY; GLOMERULUS BASEMENT MEMBRANE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RAT; SCANNING TRANSMISSION ELECTRON MICROSCOPY; TEMPERATURE; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION; ANIMAL; CHEMISTRY; DIAGNOSTIC USE; HUMAN; PROCEDURES;

ANIMALS; CONTRAST MEDIA; FERRIC COMPOUNDS; FERRITINS; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; RATS;

EID: 84907979286     PISSN: 15554309     EISSN: 15554317     Source Type: Journal    
DOI: 10.1002/cmmi.1578     Document Type: Article

References (42)

1. Fumita M, Innis RB. 'In vivo molecular imaging: ligand development and research applications', in Neuropsychopharmacology: The Fifth Generation of Progress. Lippencott Williams and Wilkins: Philadelphia PA, 2002: 411-425.
2. Kyrtsonis MC, Vassilakopoulos TP, Siakantaris MP, Kokoris SI, Gribabis DA, Dimopoulou MN, Angelopoulou MK, Pangalis GA. Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. Eur J Haematol 2004; 72(4): 252-258.
3. Stanisz GJ, Odrobina EE, Pun J, Escaravage M, Graham SJ, Bronskill MJ, Henkelman RM. T1, T2 relaxation and magnetization transfer in tissue at 3T. Magn Reson Med 2005; 54(3): 507-512.
4. Kalman FK, Geninatti-Crich S, Aime S. Reduction/dissolution of a beta-MnOOH nanophase in the ferritin cavity to yield a highly sensitive, biologically compatible magnetic resonance imaging agent. Angew Chem Int Ed Engl 2010; 49(3): 612-615.
5. Seo WS, Lee JH, Sun X, Suzuki Y, Mann D, Liu Z, Terashima M, Yang PC, McConnell MV, Nishimura DG, Dai H. FeCo/graphitic-shell nanocrystals as advanced magnetic-resonance-imaging and near-infrared agents. Nat Mater 2006; 5(12): 971-976.
6. Kim BH, Lee N, Kim H, An K, Park YI, Choi Y, Shin K, Lee Y, Kwon S, Na H, Park JG, Ahn T-Y, Kim YW, Moon WK, Choi SH, Hyeon T. Large scale synthesis of uniform and extremely small-sized iron oxide nanoparticles for high-resolution T1 magnetic resonance imaging contrast agents. J Am Chem Soc 2011; 133(32): 12624-12631.
7. Taylor KM, Rieter WJ, Lin W. Manganese-based nanoscale metal-organic frameworks for magnetic resonance imaging. J Am Chem Soc 2008; 130(44): 14358-14359.
8. Sana B, Poh CL, Lim S. A manganese-ferritin nanocomposite as an ultrasensitive T2 contrast agent. Chem Commun 2012; 48(6): 862-864.
9. Na HB, Lee JH, An K, Park YI, Park M, Lee IS, Nam DH, Kim ST, Kim SH, Kim SW, Lim KH, Kim KS, Kim SO, Hyeon T. Development of a T1 contrast agent for magnetic resonance imaging using MnO nanoparticles. Angew Chem Int Ed Engl 2007; 46(28): 5397-5401.
10. Kim T, Cho EJ, Chae Y, Kim M, Oh A, Jin J, Lee ES, Baik H, Haam S, Suh JS, Huh YM, Lee K. Urchin-shaped manganese oxide nanoparticles as pH-responsive activatable T1 contrast agents for magnetic resonance imaging. Angew Chem Int Ed Engl 2011; 50(45): 10589-10593.
11. Aime S, Frullano L, Geninatti Crich S. Compartmentalization of a gadolinium complex in the apoferritin cavity: a route to obtain high relaxivity contrast agents for magnetic resonance imaging. Angew Chem Int Ed Engl 2002; 41(6): 1017-1019.
12. Gilad AA, Walczak P, McMahon MT, Na HB, Lee JH, An K, Hyeon T, van Zijl PC, Bulte JW. MR tracking of transplanted cells with 'positive contrast' using manganese oxide nanoparticles. Magn Reson Med 2008; 60(1): 1-7.
13. Park JY, Baek MJ, Choi ES, Woo S, Kim JH, Kim TJ, Jung JC, Chae KS, Chang Y, Lee GH. Paramagnetic ultrasmall gadolinium oxide nanoparticles as advanced T1 MRI contrast agent: account for large longitudinal relaxivity, optimal particle diameter, and in vivo T1 MR images. ACS Nano 2009; 3(11): 3663-3669.
14. Tyler DJ, Robson MD, Henkelman RM, Young IR, Bydder GM. Magnetic resonance imaging with ultrashort TE (UTE) PULSE sequences: technical considerations. J Magn Reson Imag 2007; 25(2): 279-289.
15. Huang J, Zhong X, Wang L, Yang L, Mao H. Improving the magnetic resonance imaging contrast and detection methods with engineered magnetic nanoparticles. Theranostics 2012; 2(1): 86-102.
16. Khemtong C, Kessinger CW, Ren J, Bey EA, Yang SG, Guthi JS, Boothman DA, Sherry AD, Gao J. In vivo off-resonance saturation magnetic resonance imaging of alphavbeta3-targeted superparamagnetic nanoparticles. Cancer Res 2009; 69(4): 1651-1658.
17. Balchandani P, Yamada M, Pauly J, Yang P, Spielman D. Self-refocused spatial-spectral pulse for positive contrast imaging of cells labeled with SPIO nanoparticles. Magn Reson Med 2009; 62(1): 183-192.
18. Stuber M, Gilson WD, Schar M, Kedziorek DA, Hofmann LV, Shah S, Vonken EJ, Bulte JW, Kraitchman DL. Positive contrast visualization of iron oxide-labeled stem cells using inversion-recovery with ON-resonant water suppression (IRON). Magn Reson Med 2007; 58(5): 1072-1077.
19. Zhao Q, Langley J, Lee S, Liu W. Positive contrast technique for the detection and quantification of superparamagnetic iron oxide nanoparticles in MRI. NMR Biomed 2011; 24(5): 464-472.
20. Zhang L, Zhong X, Wang L, Chen H, Wang YA, Yeh J, Yang L, Mao H. T(1)-weighted ultrashort echo time method for positive contrast imaging of magnetic nanoparticles and cancer cells bound with the targeted nanoparticles. J Magn Reson Imag 2011; 33(1): 194-202.
21. Girard OM, Du J, Agemy L, Sugahara KN, Kotamraju VR, Ruoslahti E, Bydder GM, Mattrey RF. Optimization of iron oxide nanoparticle detection using ultrashort echo time pulse sequences: comparison of T1, T2*, and synergistic T1- T2* contrast mechanisms. Magn Reson Med 2011; 65(6): 1649-1660.
22. Meldrum FC, Douglas T, Levi S, Arosio P, Mann S. Reconstitution of manganese oxide cores in horse spleen and recombinant ferritins. J Inorg Biochem 1995; 58(1): 59-68.
23. Meldrum FC, Heywood BR, Mann S. Magnetoferritin: in vitro synthesis of a novel magnetic protein. Science 1992; 257(5069): 522-523.
24. Uchida M, Terashima M, Cunningham CH, Suzuki Y, Willits DA, Willis AF, Yang PC, Tsao PS, McConnell MV, Young MJ, Douglas T. A human ferritin iron oxide nano-composite magnetic resonance contrast agent. Magn Reson Med 2008; 60(5): 1073-1081.
25. Jordan VC, Caplan MR, Bennett KM. Simplified synthesis and relaxometry of magnetoferritin for magnetic resonance imaging. Magn Reson Med 2010; 64(5): 1260-1266.
26. Bulte JW, Douglas T, Mann S, Frankel RB, Moskowitz BM, Brooks RA, Baumgarner CD, Vymazal J, Frank JA. Magnetoferritin. Biomineralization as a novel molecular approach in the design of iron-oxide-based magnetic resonance contrast agents. Invest Radiol 1994; 29(Suppl 2): S214-216.
27. Cormode DP, Jarzyna PA, Mulder WJ, Fayad ZA. Modified natural nanoparticles as contrast agents for medical imaging. Adv Drug Deliv Rev 2010; 62(3): 329-338.
28. Arosio P, Ingrassia R, Cavadini P. Ferritins: a family of molecules for iron storage, antioxidation and more. Biochim Biophys Acta 2009; 1790(7): 589-599.
29. Bulte JW, Douglas T, Mann S, Vymazal J, Laughlin PG, Frank JA. Initial assessment of magnetoferritin biokinetics and proton relaxation enhancement in rats. Acad Radiol 1995; 2(10): 871-878.
30. Beeman SC, Georges JF, Bennett KM. Toxicity, biodistribution, and ex vivo MRI detection of intravenously injected cationized ferritin. Magn Reson Med 2013; 69(3): 853-861.
31. Kumar VB, Mohanta D. Formation of nanoscale tungsten oxide strutures and colouration characteristics. Bull Mater Sci 2012; 34(3): 435-442.
32. Si PZ, Choi CJ, Bruck E, Klaasse JCP, Geng DY, Zhang ZD. Synthesis, structure and magnetic properties of iron-doped tungsten oxide nanorods. Phys B Condensed Matter 2007; 392(1-2): 154-158.
33. Kaszuwara W, Leonowicz M, Kozubowski JA. The effect of tungsten addition on the magnetic properties and microstructure of SmFeN-a_Fe nanocomposites. Mater Lett 1999; 42(6): 383-386.
34. Escobar C, Cid-Dresdner H, Kittl P, Dumler I. The relation between light wolframite and common wolframite. Am Minerol 1971; 56: 489-498.
35. Resnick D, Gilmore K, Idzerda Y, Klem M, Smith E, Douglas T. Modeling of the magnetic behavior of γ-Fe 2 O 3 nanoparticles mineralized in ferritin. J Appl Phys 2004; 95(11): 7127-7129.
36. Vasalatiy O, Zhao P, Zhang S, Aime S, Sherry AD. Catalytic effects of apoferritin interior surface residues on water proton exchange in lanthanide complexes. Contrast Media Mol Imag 2006; 1(1): 10-14.
37. Bennett KM, Zhou H, Sumner JP, Dodd SJ, Bouraoud N, Doi K, Star RA, Koretsky AP. MRI of the basement membrane using charged nanoparticles as contrast agents. Magn Reson Med 2008; 60(3): 564-574.
38. Beeman SC, Zhang M, Gubhaju L, Wu T, Bertram JF, Frakes DH, Cherry BR, Bennett KM. Measuring glomerular number and size in perfused kidneys using MRI. Am J Physiol Renal Physiol 2011; 300(6): F1454-1457.
39. Bennett KM, Bertram JF, Beeman SC, Gretz N. The emerging role of MRI in quantitative renal glomerular morphology. Am J Physiol Renal Physiol 2013; 304(10): F1252-F1257.
40. Danon D, Goldstein L, Marikovsky Y, Skutelsky E. Use of cationized ferritin as a label of negative charges on cell surfaces. J Ultrastruct Res 1972; 38(5): 500-510.
41. Mitchell MD, Kundel HL, Axel L, Joseph PM. Agarose as a tissue equivalent phantom material for NMR imaging. Magn Reson Imag 1986; 4(3): 263-266.
42. Reichenbach JR, Hackländer Th, Harth T, Hofer M, Rassek M, Mödder U. 1H T1 and T2 measurements of the MR imagingcontrast agents Gd-DTPA and Gd-DTPA BMA at 1.5 T. Eur Radiol 1997; 7(2): 264-274.